Researchers identified immune activity changes in first-trimester placenta and decidua samples profiled through single-cell RNA sequencing.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.
The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter.
The company feels it could be an attractive target for mergers, but is also keeping an eye out for IP acquisition options of its own.
The company said its revenue increase was driven by gains in test volume, particularly in miscarriage analysis and preimplantation genetic screening for couples undergoing IVF.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.